Cargando…

Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study

PURPOSE: Chemotherapy is the standard care for patients with incurable advanced gastric cancer. Whether or when the addition of gastrectomy to chemotherapy improves survival of advanced gastric cancer patients with a single noncurable factor remains controversial. We aimed to evaluate the superiorit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wei, Jiang, Huiqin, Yu, Yiyi, Wang, Yan, Wang, Zhiming, Cui, Yuehong, Shen, Kuntang, Shen, Zhenbin, Fang, Yong, Liu, Tianshu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407509/ https://www.ncbi.nlm.nih.gov/pubmed/30881125 http://dx.doi.org/10.2147/CMAR.S192570

Ejemplares similares

Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO‐CLASSIC Study
por: Yu, Yiyi, et al.
Publicado: (2019)

Is noncurative gastrectomy always a beneficial strategy for stage IV gastric cancer?
por: Lee, Chang Min, et al.
Publicado: (2017)

Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer.
por: Maehara, Y., et al.
Publicado: (1992)

Evaluation of additional gastrectomy after noncurative endoscopic submucosal dissection for early gastric cancer
por: Makimoto, Shinichiro, et al.
Publicado: (2022)

Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
por: Tang, Zhaoqing, et al.
Publicado: (2022)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
por: Yu, Shan, et al.
Publicado: (2020)

Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma
por: Li, Wei, et al.
Publicado: (2020)

Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
por: Li, Qian, et al.
Publicado: (2016)

Additional laparoscopic gastrectomy after noncurative endoscopic submucosal dissection for early gastric cancer: A single-center experience
por: Tian, Yan-Tao, et al.
Publicado: (2019)

Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)
por: Cui, Yuehong, et al.
Publicado: (2023)

Platelet-to-lymphocyte ratio and lymphocyte-to-white blood cell ratio predict the efficacy of neoadjuvant chemotherapy and the prognosis of locally advanced gastric cancer patients treated with the oxaliplatin and capecitabine regimen
por: Tang, Cheng, et al.
Publicado: (2018)

The Clinical Significance and Management of Noncurative Endoscopic Resection in Early Gastric Cancer
por: Heo, Jun, et al.
Publicado: (2013)

Effect of additional surgery after noncurative endoscopic submucosal dissection for early gastric cancer
por: Yamanouchi, Kohei, et al.
Publicado: (2016)

Risk Factors and Timing of Additional Surgery after Noncurative ESD for Early Gastric Cancer
por: Duan, Kaipeng, et al.
Publicado: (2022)

The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
por: Tang, Zhaoqing, et al.
Publicado: (2022)

A Case of Noncuratively Resected Gastric Cancer and Postoperative Chemotherapy with S-1 Monotherapy Resulting in Long-Term Survival for Over 8 Years
por: Suh, Byoung Jo
Publicado: (2017)

Phase I study of adjuvant chemotherapy with nab‐paclitaxel and S‐1 for stage III Lauren's diffuse‐type gastric cancer after D2 resection (NORDICA study)
por: Cui, Yuehong, et al.
Publicado: (2022)

Spiritual Well-being in Patients With Metastatic Colorectal Cancer Receiving Noncurative Chemotherapy: A Qualitative Study
por: Rohde, Gudrun, et al.
Publicado: (2017)

PREOPERATIVE CHEMOTHERAPY VERSUS UPFRONT SURGERY FOR ADVANCED GASTRIC CANCER: A PROPENSITY SCORE MATCHING ANALYSIS
por: Hong, Stefany, et al.
Publicado: (2023)

Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study
por: Zhang, Lingyun, et al.
Publicado: (2022)

Yoga for Young Adults With Noncurative Cancer: A Brief Report
por: Woodside, Hillary, et al.
Publicado: (2018)

External Validation of the eCura System for Undifferentiated-Type Early Gastric Cancer with Noncurative Endoscopic Resection
por: Yang, Hyo-Joon, et al.
Publicado: (2023)

Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review
por: Fiflis, Stylianos, et al.
Publicado: (2023)

Corrigendum to: External Validation of the eCura System for Undifferentiated-Type Early Gastric Cancer with Noncurative Endoscopic Resection
por: Yang, Hyo-Joon, et al.
Publicado: (2023)

Should All Undifferentiated Early Gastric Cancer Patients Undergoing Noncurative Endoscopic Resection Be Sent to the Operating Room?
por: Kim, Jung-Wook, et al.
Publicado: (2023)

Outcomes of esophagectomy after noncurative endoscopic resection of early esophageal cancer
por: Dermine, Solène, et al.
Publicado: (2019)

Expanded endoscopic therapy criteria should be cautiously used in intramucosal gastric cancer
por: Wang, Hongshan, et al.
Publicado: (2016)

Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer
por: Zhu, Mengxuan, et al.
Publicado: (2022)

NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer
por: Cui, Yuehong, et al.
Publicado: (2021)

Survival time and prognostic factors of patients with initial noncurative colorectal liver metastases
por: Liu, Qizhi, et al.
Publicado: (2017)

A concordant expression pattern of fatty acid synthase and membranous human epidermal growth factor receptor 2 exists in gastric cancer and is associated with a poor prognosis in gastric adenocarcinoma patients
por: LI, HE, et al.
Publicado: (2015)

Machine learning models for predicting one-year survival in patients with metastatic gastric cancer who experienced upfront radical gastrectomy
por: Zhang, Cheng, et al.
Publicado: (2022)

The IGCA staging system is more accurate than AJCC7 system in stratifying survival of patients with gastric cancer in stage III
por: Shu, Ping, et al.
Publicado: (2017)

Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis
por: Wu, Pei, et al.
Publicado: (2018)

A Meta-Analysis: Methylenetetrahydrofolate Reductase C677T Polymorphism in Gastric Cancer Patients Treated with 5-Fu Based Chemotherapy Predicts Serious Hematologic Toxicity but Not Prognosis
por: Tang, Cheng, et al.
Publicado: (2018)

Adjuvant Chemotherapy for Elderly Patients with Gastric Cancer after D2 Gastrectomy
por: Jin, Ying, et al.
Publicado: (2013)

Asparaginyl endopeptidase promotes the invasion and metastasis of gastric cancer through modulating epithelial-to-mesenchymal transition
por: Cui, Yuehong, et al.
Publicado: (2016)

Predictors of lymph node metastasis and residual tumor in early gastric cancer patients after noncurative endoscopic resection: a systematic review and meta-analysis
por: Jiang, Bolun, et al.
Publicado: (2020)

The safety and efficacy of laparoscopic gastrectomy for patients with locally advanced gastric cancer following neoadjuvant chemotherapy
por: Liu, Lihang, et al.
Publicado: (2022)

The Safety and Feasibility of Laparoscopic Gastrectomy after Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
por: Ge, Rui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g52rm17gckvugtjf09havvgbao